Repotrectinib CAS：1802220-02-5 is a potent, oral third-generation tyrosine kinase inhibitor targeting ROS1 and NTRK fusions. It overcomes multiple resistance mutations in ROS1-positive NSCLC and NTRK fusion-positive solid tumors, with strong CNS activity. It is clinically approved for targeted cancer therapy.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
